Showing results (11-20 of 81) with videos related to

Sort By:
Pageof 9
Frontiers in Reproductive Health|October 28, 2022
A Summary of Online Enquiries Submitted to Anti-doping Hotline 2005-2018Lena Ekström, Susanne Broström, Marja-Liisa Dahl, et al.
Journal of Clinical Psychopharmacology|December 31, 2010
High correlation between serum and cerebrospinal fluid olanzapine concentrations in patients with schizophrenia or schizoaffective disorder medicating with oral olanzapine as the only antipsychotic drugElisabeth Skogh, Ingemar Sjödin, Martin Josefsson, et al.
Pharmacoepidemiology and Drug Safety|December 17, 2009
Muscle toxicity with statinsKarin Hedenmalm, Gunnar Alvan, Patrik Ohagen, et al.
Clinical Pharmacokinetics|August 27, 2014
Impact of cytochrome P450 2C19 polymorphisms on citalopram/escitalopram exposure: a systematic review and meta-analysisMing Chang, Gunnel Tybring, Marja-Liisa Dahl, et al.
Pharmacogenetics and Genomics|March 16, 2013
Influence of CYP1A1/CYP1A2 and AHR polymorphisms on systemic olanzapine exposureMao M Söderberg, Tore Haslemo, Espen Molden, et al.
Therapeutic Drug Monitoring|August 19, 2008
ABCB1 polymorphisms influence steady-state plasma levels of 9-hydroxyrisperidone and risperidone active moietyArzu Gunes, Edoardo Spina, Marja-Liisa Dahl, et al.
British Journal of Clinical Pharmacology|February 20, 2002
Molecular genetics of CYP2D6: clinical relevance with focus on psychotropic drugsLeif Bertilsson, Marja-Liisa Dahl, Per Dalén, et al.
Psychopharmacology|November 15, 2006
Serotonin and dopamine receptor gene polymorphisms and the risk of extrapyramidal side effects in perphenazine-treated schizophrenic patientsArzu Gunes, Maria Gabriella Scordo, Peeter Jaanson, et al.
European Journal of Clinical Pharmacology|January 22, 2008
Further evidence for the association between 5-HT2C receptor gene polymorphisms and extrapyramidal side effects in male schizophrenic patientsArzu Gunes, Marja-Liisa Dahl, Edoardo Spina, et al.
The Journal of Clinical Psychiatry|May 17, 2007
Impact of CYP1A2 and CYP2D6 polymorphisms on drug metabolism and on insulin and lipid elevations and insulin resistance in clozapine-treated patientsKristina I Melkersson, M Gabriella Scordo, Arzu Gunes, et al.
Pageof 9